Hemolytic anemia after switching from infliximab originator to biosimilar CT-P13 in a patient with inflammatory bowel disease: A case report.
Anne S StrikGeert R D'HaensMark LöwenbergPublished in: Clinical case reports (2019)
Available data on switching from originator infliximab to CT-P13 in patients with inflammatory bowel disease are reassuring regarding safety and efficacy outcomes. However, monitoring of such patients, especially in the early phase after switching, is important given the possibility that rare side effects might occur, as illustrated here.
Keyphrases
- end stage renal disease
- patients with inflammatory bowel disease
- chronic kidney disease
- computed tomography
- ulcerative colitis
- image quality
- ejection fraction
- newly diagnosed
- contrast enhanced
- dual energy
- prognostic factors
- peritoneal dialysis
- positron emission tomography
- magnetic resonance imaging
- case report
- adipose tissue
- metabolic syndrome
- big data
- iron deficiency
- artificial intelligence
- data analysis
- glycemic control